ADAP

Adaptimmune Therapeutics
ADAP

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

47 hedge funds and large institutions have $260M invested in Adaptimmune Therapeutics in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

more capital invested

Capital invested by funds: $ → $

more funds holding in top 10

Funds holding in top 10: →

less funds holding

Funds holding: →

less first-time investments, than exits

New positions opened: | Existing positions closed:

29% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 14

Holders
47
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$3.26M
2
+$2.33M
3
+$2.04M
4
AC
Ascend Capital
California
+$1.34M
5
NLVP
New Leaf Venture Partners
New York
+$1.03M

Top Sellers

1
-$5.76M
2
-$1.97M
3
-$1.1M
4
VIA
Vident Investment Advisory
Georgia
-$551K
5
DCM
DAFNA Capital Management
California
-$514K
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$513K
27
$469K
28
$420K
29
$408K
30
$326K
31
$261K
32
$240K
33
$220K
34
$206K
35
$203K
36
$196K
37
$170K
38
$160K
39
$131K
40
$130K
41
$91K
42
$83K
43
$67K
44
$12K
45
$8K
46
$8K
47
$2K
48
–
49
–
50
–
1
2
3